PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+11.58%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$3.59B
AUM Growth
+$3.59B
(-23%)
Cap. Flow
-$646M
Cap. Flow
% of AUM
-18%
Top 10 Holdings %
Top 10 Hldgs %
50.81%
Holding
126
New
21
Increased
12
Reduced
43
Closed
26
Top Buys
| 1 |
Janux Therapeutics
JANX
|
$43.8M |
| 2 |
Insulet
PODD
|
$23.5M |
| 3 |
Inhibikase Therapeutics
IKT
|
$19.3M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$17.6M |
| 5 |
Penumbra
PEN
|
$17.4M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$76.6M |
| 2 |
Biohaven
BHVN
|
$74.2M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$61.4M |
| 4 |
Apogee Therapeutics
APGE
|
$43.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$35.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.16B
| $297M | 8.18% | 6,392,106 +76,173 | +1% | +$3.54M |
|
2
Arcellx
ACLX
$3.85B
| $267M | 7.35% | 3,478,888 -409,781 | -11% | -$31.4M |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $228M | 6.29% | 24,245,952 -3,811,504 | -14% | -$35.9M |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $206M | 5.68% | 3,680,473 +120,259 | +3% | +$6.73M |
|
5
Nuvalent
NUVL
$5.52B
| $205M | 5.65% | 2,619,977 -359,258 | -12% | -$28.1M |
|
6
Iovance Biotherapeutics
IOVA
$807M
| $164M | 4.51% | 22,112,266 -4,505,443 | -17% | -$33.3M |
|
7
Vaxcyte
PCVX
$4B
| $141M | 3.88% | 1,718,417 -309,191 | -15% | -$25.3M |
|
|
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $108M | 2.97% | 1,288,328 -333,887 | -21% | -$27.9M |
|
|
CNTA
9
Centessa Pharmaceuticals
CNTA
$2.25B
| $106M | 2.93% | 6,349,220 +66,930 | +1% | +$1.12M |
|
10
Praxis Precision Medicines
PRAX
$958M
| $102M | 2.82% | 1,329,735 +165,700 | +14% | +$12.8M |
|
11
Artivion
AORT
$2.07B
| $79.9M | 2.2% | 2,793,703 | – | – |
|
12
MeiraGTx Holdings
MGTX
$587M
| $76.6M | 2.11% | 12,581,103 | – | – |
|
13
Edgewise Therapeutics
EWTX
$1.51B
| $71.7M | 1.98% | 2,685,537 +355,243 | +15% | +$9.48M |
|
|
14
Soleno Therapeutics
SLNO
$3.6B
| $67.5M | 1.86% | 1,501,040 -1,703,936 | -53% | -$76.6M |
|
15
Immatics
IMTX
$619M
| $66.7M | 1.84% | 9,383,456 +1,297,297 | +16% | +$9.22M |
|
|
16
Insulet
PODD
$23.9B
| $60.6M | 1.67% | 232,269 +90,000 | +63% | +$23.5M |
|
17
Spyre Therapeutics
SYRE
$996M
| $59.9M | 1.65% | 2,574,723 -297,824 | -10% | -$6.93M |
|
18
Astria Therapeutics
ATXS
$349M
| $58M | 1.6% | 6,485,420 | – | – |
|
19
Evolus
EOLS
$494M
| $56.8M | 1.57% | 5,145,846 -210,776 | -4% | -$2.33M |
|
20
Axsome Therapeutics
AXSM
$6.05B
| $56.2M | 1.55% | 664,074 -118,770 | -15% | -$10M |
|
|
CRGX
21
DELISTED
CARGO Therapeutics
CRGX
| $53.1M | 1.46% | 3,683,004 | – | – |
|
22
Immunovant
IMVT
$2.56B
| $53M | 1.46% | 2,139,199 -239,563 | -10% | -$5.93M |
|
23
Protagonist Therapeutics
PTGX
$3.67B
| $49.1M | 1.35% | 1,271,662 -102,901 | -7% | -$3.97M |
|
|
24
Apogee Therapeutics
APGE
$2.17B
| $47.4M | 1.31% | 1,047,232 -967,775 | -48% | -$43.8M |
|
25
Aldeyra Therapeutics
ALDX
$351M
| $46.3M | 1.28% | 9,275,851 | – | – |
|